14.08.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC PARTNER HAPLOGEN ENTERS INTO COLLABORATION WITH BAYER
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC PARTNER HAPLOGEN ENTERS INTO COLLABORATION WITH BAYER
14.08.2018 / 08:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* FOCUS ON PULMONARY DISEASES WITH HIGH UNMET MEDICAL NEED
* INTEGRATED HAPLOGEN-BAYER COLLABORATION BUILDS UPON PULMONARY PORTFOLIO
CREATED BY EVOTEC AND HAPLOGEN
* EVOTEC WILL PARTICIPATE IN UNDISCLOSED UPFRONT AS WELL AS POTENTIAL
MILESTONE AND ROYALTY-BASED PAYMENTS FROM BAYER TO HAPLOGEN
Hamburg, Germany, 14 August 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that Haplogen GmbH ("Haplogen"), a Vienna-based
biotechnology company and collaboration partner of Evotec, has entered into
a multi-year drug discovery and development collaboration with Bayer AG to
identify new therapeutics with applications in pulmonary diseases such as
chronic obstructive pulmonary disease ("COPD").
Since Haplogen and Evotec began collaborating in 2012, collectively, they
built a robust portfolio of pulmonary therapeutic programmes based on the
industry-leading drug discovery platforms and know-how of both companies.
The target-based approach will now be broadened under the terms of the new
Haplogen collaboration with Bayer.
COPD is a common and heterogeneous respiratory disease that causes
breathlessness and predisposes to exacerbations and serious illness.
Respiratory viral infections are one frequent cause of COPD exacerbations.
One possible treatment approach for COPD exacerbations is to disrupt the
multiplication of the responsible virus by inhibiting its replication. The
goal of the research alliance from Haplogen and Bayer is to develop new
antiviral compounds addressing the high unmet medical need in reducing COPD
exacerbations.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "Our alliance
with Haplogen has proven that both companies and teams are united by the
same spirit and objectives under a very efficient "virtual"
performance-based biotech business model. With the addition of Bayer's
excellent expertise, we have high aspirations for this partnership and look
forward to bringing new and better treatments to patients living with
pulmonary diseases."
Dr Georg Casari, Chief Executive Officer of Haplogen, commented: "This
partnership with Bayer will transform our discoveries to therapies with
benefit to patients in need. At Haplogen we are proud to see our work in
research and development validated and approved by Bayer's commitment to
this partnership. It has been the outcome of an excellent and professional
collaboration with our partner Evotec."
As part of the new Haplogen collaboration, Bayer receives an exclusive
license to worldwide rights to programmes developed within the collaboration
between Haplogen and Evotec. Evotec will participate in undisclosed upfront
as well as potential milestone and royalty-based payments from Haplogen.
Further financial terms of the Haplogen-Bayer collaboration are not
disclosed.
ABOUT HAPLOGEN GMBH
Haplogen is a privately held biotechnology company in Vienna, Austria, with
drug discovery programs to combat viral infectious and other diseases.
Haplogen's therapeutic programs are based on novel mechanisms that have been
discovered using a functional genomics platform based on haploid genetics in
human cell lines. Haplogen was founded in 2010 as a spin-out of CeMM, the
Research Center for Molecular Medicine of the Austrian Academy of Sciences.
For more information on Haplogen visit: www.haplogen.com.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 80 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with e.g. with Sanofi in the field of diabetes,
with Pfizer in the field of tissue fibrosis and Celgene in the field of
neurodegenerative diseases. For additional information please go to
www.evotec.com/ and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
14.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
713931 14.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT